AU676468B2 - Recombinant gibberellin DNA and uses thereof - Google Patents

Description

OP1' DATE 03/09/93 APPLN. ID 36594/93 Ili I 1111111 AOJP DATE 11/11/93 PCT NUMBER~ PCT/US93/01121 11I11I111111111111111111 i ii111 nhmn1ul11 AU9336594.

(PCi) (51j) International Patent Classification 5 C07H 21/02, 21/04, C12Q 1/68 C12N 15/63'~15/70,"5/10 C1l2N 1/21, 1/15, G01 N33153 A61K 35/14 (11) International Publication Number: (43) International Publication Date: WO 93/16096 19 August 1993 (19.08.93) (21) International Application Number: PCT/US93/01 121 (22) International Filing Date: 5 Februar 1993 (05,02,93) Priority data: 07/844,300 08/008,996 18 February 1992(118.02.92) US 27 January 1993 (27.01.93) US (74) Agents: CIMBALA, Michele, A. et al.; Sterne, Kessler, Goldstein Fox, 1225 Connecticut Avenue, Suite 300, Washington, DC 20036-2678 (US).

(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published With international search report.

(71) Applicant: THE GENERAL HOSPITAL CO RPORA- TION [US/US]; Fruit Street, Boston, MA 02114 (US).

(72) Inventors: SUN, Tai-ping 910 Constitution Drive, Apt.

403, Durham, NC 27705 GOODMAN, Howad, M. 10 The Ledges Road, Newton Centre, M4A 02159 AUSUBEL,Frederick, M. 271 Lake Avenue, Newton, MA 02161 (US).

(54) Title: RECOMBINANT GIBBERELLIN DNA AND USES THEREOF 1 GAATTCCTTT TTTTTTTTTT TAA.AGCCATG TCTCTTCAGT ATCATGTTCT 51 AAACTCCATI 101 CTTCTTCTTI 151 AAATCCAGAA 201 CATTAATTCT 251 AACAGCTTCA 301 AATGCATTCA 351 AACGGACGGG 401 TGATCGATGC 451 ATCGCCGAGA 501 CTCTTATCAT 551 GATCATGGAA CCAAGTACAA CCTTTCTCAC

CCTTACCATC

GCOGTTCCAT

CAAGAGGTTC

AGGAGAAGAT

AAGAAGCAGT

GAAATTACGA

CGGAGATAAA

ACCAACTTTC

GATCGTCTCA

TCAGGATCTC

ACATTGTTCA

AACATGATTT

GCTCCTCAGA

GAAGAGTGTG

TATCGGCTTA

ACTCCGGCGT

CGATGGTTCT

TCAATACCCT

TTCTACTAAP-Z

CTCTCAATGT

AAGCTTCGAA

GCCTCTAATA

TTAGTGTTGG

AAAACGATCT

CGATACAGCT

TTCCCTCCGC

TGGGGAGATG

TGCATGCGTC

ACAAAGGAAT

ACAACAATAT

CGCTAGAGAC

CTCAAGAATA

CATGAGTGGC

AAGTAAITAGT

TGAGAAACCT

TGGGTTGCAT

CGTGAP ATGG

CGTATCTCTT

GTTGCTCTAA

CACGTTTTTC TCTCTTTCCT CATCAATGCA 1 CCIGGAAAATA TTGGGAAGCT AGAAGACGAA AATGATGAGC ATATGCCAAT (57) Abstract The present invention concerns the cloning and sequencing of DNA corresponding to the GAl locus of A. thaliana which encodes ent-kaurene synthetase, to vectors containing said DNA, to vectors capable of expressing said DNA, and to hosts transformed with said vectors. The invention further concerns the use of the GAl gene, and regulatory regions thereof, in the generation of chimeric and transgenic plants.

1 RECOMBJNANT GIBBERELLIN DNA AND USES THEREOF Field of the Invention The invention pertains to recombinant DNA technology. Specifically, the invention relates to cDNA and genomic DNA corresponding to the GA1 locus of Arabidopsis thaliana which encodes ent-kaurene synthetase, expression vectors containing such genes, hosts transformed with such vectors, the regulatory regions of the GA1 gene, the use of such regulatory regions to direct the expression of operably-linked heterologous genes in S 10 transgenic plants, the GA1 protein substantially free of other A. thaliana *proteins, e* *o •g eg o WO 93/16096 PC/US93/01121 -2antibodies capable of binding to the GAl protein, and to methods of assaying for the expression of the GA1 gene and the presence of GA1 protein in plant cells and tissues.

Background of the Invention A. Gibberellins Gibberellins (GAs) are a family of diterpenoid plant growth hormoies required for seed germination, leaf expansion, stem elongation, flowering, and fruit set. GAs have been the subject of many physiological, and biochemical studies, and a variety of plant mutants with altered patterns of GA biosynthesis or response have been studied (Graebe, Ann. Rev. Plant Physiol. 38:419- 465 (1987)). However, none of the genes involved in GA synthesis have yet been cloned.

One of the most extensive genetic studies of GA mutants has been carried out by Koornneef et al. (Theor. Appl. Genet. 58:257-263 (1980); Koornneef et al., Genet. Res. Camb. 41:57-68 (1983)) in the small crucifer, Arabidopsis thaliana. Using ethylmethanesulfonate (EMS) and fast neutron mutagenesis, Koornneef has isolated nine alleles mapping to the GAI locus of A. thaliana (Koornneef et al. (Theor. Appl. Genet. 58:257-263 (1980); Koornneef et al., Genet. Res. Camb. 41:57-68 (1983)).

A. thaliana gal mutants are non-germinating, GA-responsive, malesterile dwarfs whose phenotype can be converted to wild-type by repeated application of GA (Koornneef and van der Veen, Theor. Appl. Genet. 58:257- 263 (1980)). Koornneef et al. used three independent alleles generated by fast neutron bombardment (31.89, 29.9 and 6.59) and six independent alleles (NG4, NG5, d69, A428, d352 and Bo27) generated by ethyl methane sulfonate mutagenesis to construct a fine-structure genetic map of the A. thaliana GAl WO 93/16096 PCT/US93/01121 -3locus (Figure 2A). One of the fast-neutron-generated mutants, 31.89, failed to recombine with the six alleles indicated in Figure 2A, and was classified as an intragenic deletion (Koornneef et al., Genet. Res. Camb. 41:57-68 (1983)).

The enzyme encoded by the GAl gene is involved in the conversion of geranylgeranyl pyrophosphate to ent-kaurene (Barendse and Koornneef, Arabidopsis Inf. Serv. 19:25-28 (1982); Barendse et al., Physiol. Plant.

67:315-319 (1986); Zeevaart, in Plant Research '86, Annual Report of the MSU-DOE Plant Research Laboratory, 130-131 (East Lansing, MI, 1986)), a key intermediate in the biosynthesis of GAs (Graebe, Ann.

Rev. Plant Physiol. 38:419-465 (1987)).

12 entkaurene I synthetase ent-karene Even though ent-kaurene synthetase'has been partially purified from a variety of plants (Duncan, Plant Physiol. 68:1128-1134 (1981)), it's amino acid sequence has yet to be determined.

By examining the molecular lesions in several gal alleles, a direct correlation of the genetic and physical maps of the GAl locus was established and a recombination rate of 10 5 cM per nucleotide was determined for this region of the A. thaliana genome. (Koornneef, Genet. Res. Comb. 41:57-68 (1983)).

Although gal mutants have been available for some time, the cloning of the GAl gene has remained elusive. The difficulty associated with cloning WO 93/16096 PCT/US93/01121 -4the GA1 gene and other genes involved in GA biosynthesis is most likely caused by the unavailability of efficient transformation/ selection systems as well as the lack of available protein sequences.

B. Gene Cloning The ability to identify and clone a particular, desired gene sequence from a virus, prokaryote or eukaryote is of tremendous significance to molecular biology. Such cloned gene sequences can be used to express a desired gene product and therefore can potentially be used for applications ranging from catalysis to gene replacement.

A variety of methods have been developed for isolating and cloning desired gene sequences. Early methods permitted only the identification and isolation of gene sequences which possessed a unique property such as proximity to a prophage integration site, capacity for self-replication, distinctive molecular weight, extreme abundance, etc. (The Bacteriophage Lambda, A.D. Hershey, ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1971); Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY (1972); Molecular Biology of the Gene, Watson, J.D. et al., (4th ed.) Benjamin/Cummings, Menlo Park, CA (1987); Darnell, J. et al. Molecular Biology, Scientific American Books, NY, NY (1986)). Because these methods relied upon distinctive properties of a gene sequence, they were largely (or completely) unsuitable for identifying and cloning most gene sequences.

In order to identify desired gene sequences which lacked a distinctive property, well characterized genetic systems (such as Escherichia coli, Saccharomyces cerevisiae, maize, mammalian cells, etc.) have been exploited.

In accordance with this methodology, cells are mutagenized by chemicals, such as UV light, hydroxylamine, etc. (Miller, J.H. Experiments in Molecular WO 93/16096 PCr US 93/0 1 121 Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY (1972)), or by genetic means, such as transposon tagging (Davis, R.W. et al. A Manual for Genetic Engineering, Advanced Bacterial Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY (1980)), to produce mutants having discernible genetic deficiencies. A desired gene sequence is then identified by its capacity to complement remedy) the genetic deficiencies of such mutant cells.

Such genetic identification permitted the genetic characterization of the gene sequences, and the construction of genetic maps which localized the gene sequence to a region of a particular chromosome (Taylor, Bacteriol. Rev.

34:155 (1970)). With the advent of recombinant DNA technologies, it became possible to clone to physically isolate) such genetically characterized gene sequences. Random fragments of a genome could be introduced into selfreplicating vectors to produce gene libraries, each of whose members contain a unique DNA fragment (Maniatis, T. et al., In: Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY (1982)). By screening the members of such libraries for those capable of complementing the deficiency of a mutant cell, it was possible to clone the desired gene sequence.

Although these methods permit the identification and cloning of many gene sequences, they may be employed only where a host cell exists which has a mutation conferring a discernible deficiency, and the gene sequence can be cloned into a gene sequence delivery system (such as a vector) capable of entering the host cell and being expressed.

The capacity to physically isolate certain gene sequences has led to the development of methods which are capable of isolating a desired gene sequence even in the absence of mutations or vectors.

In one such technique, known as "chromosome walking," a desired sequence can be obtained by isolating a gene sequence which is capable of hybridizing to a particular reference sequence. This isolated gene sequence WO 93/16096 PCT/US93/01121 -6is then employed as a reference sequence in a subsequent hybridization experiment in order to clone a gene sequence which is adjacent to, and which partially overlaps, the originally isolated sequence. This newly isolated sequence will be physically closer to the desired gene sequence than was the originally isolated sequence. This process is repeated until the desired gene sequence has been obtained. As will be appreciated, the ability to clone a gene sequence, in the absence of genetic mutants or vectors, requires some initial information concerning the nucleotide sequence or restriction endonuclease digestion profile of the desired sequence.

Alternatively, the chromosome of a virus or cell can be characterized to produce a physical map based on either nucleotide sequence or restriction endonuclease cleavage data an RFLP map). Using such a map, restriction fragments of the chromosome can be cloned without any prior determination as to their genetic function.

More recently, gene cloning has been achieved by producing synthesizing oligonucleotide molecules whose sequence has been deduced from the amino acid sequence of an isolated protein, by forming cDNA copies of isolated RNA transcripts, by differential colony or library subtractive hybridizations using either two different RNA sources, or cDNA and RNA.

Although these methods may be employed even in the absence of either mutants or a gene sequence delivery system, they permit a desired gene sequence to be identified and cloned only if sequences naturally linked to the desired sequence have been characterized and isolated, or if the sequence or restriction map of such sequences has been obtained. Since such data is often unavailable, these methods are often incapable of use in identifying and cloning a desired gene sequence.

Two general approaches have been described for cloning sequences that are present in one strain and absent in another. The first approach, differential screening, has been used to clone the esc gene from Drosophila.

Using genomic DNA from strains with and without a deletion to probe replicas WO 93/16096 PCrUS93/01121 -7of a genomic library poses technical difficulties which become daunting for large genomes. In addition, the deletion must cover at least one entire insert in the genomic library which does not contain any repeated sequences.

The second approach, competitive hybridization, provides an elegant alternative to differential screening. This technique was used by Lamar et al.

(Cell 37:171-177 (1984)) to isolate clones specific for the human Y chromosome. In accordance with this method, an excess of sheared DNA from a human female is denatured and reannealed along with a small amount of DNA from a male (the male-derived DNA having been previously treated to have sticky ends). Most of the male DNA reassociated with the sheared DNA yielding unclonable fragments lacking sticky ends. Fragments unique to the Y chromosome, however, could only reassociate with the complementary restricted strand (derived from the Y chromosome). Such reassociation thus formed clonable fragments with sticky ends. This technique has also been used successfully to clone DNA corresponding to deletions in the Duchenne muscular dystrophy locus, and choroideremia.

Unfortunately, the competitive hybidization method does not provide a large enough degree of enrichment. For example, enrichments of about one hundred fold were obtained for the sequences of interest in the above experiments. With enrichments of such low magnitude, the technique is practical only when dealing with large deletions. Indeed, even if the deletion covered 0.1 of the genome, many putative positive clones have to be tested individually by labeling and probing genomic Southern blots (Southern, J.

Molec. Biol. 98:503-517 (1975)). The method as it stands, then, is not practical for deletions on the order of 1 kbp (kilobasepair) unless one is dealing with a small prokaryotic genome.

Thus, in summary, the ability to clone DNA corresponding to a locus defined only by a mutation is a relatively simply matter when working with E. coli, S. cerevisiae or other organisms in which transformation and WO 93/16096 PCT/US93/01121 -8complementation with genomic libraries is feasible. Chromosome walking techniques may be used in other organisms to clone genetically defined loci if the mutant was obtained by transposon tagging, if the locus can be linked to markers in an RFLP map, or if an ordered library for the genome exists.

Unfortunately, there are numerous organisms in which mutants with interesting phenotypes have been isolated but for which such procedures have not been developed, such as the GA synthesis mutants of A. thaliana. Thus, many gene sequences cannot be isolated using the above methods.

C. Transgenic and Chimeric Plants Recent advances in recombinant DNA and genetic technologies have made it possible to introduce and express a desired gene sequence in a recipient plant. Through the use of such methods, plants have been engineered to contain gene sequences that are not normally or naturally present in an unaltered plant. In addition, these techniques have been used to produce plants which exhibit altered expression of naturally present gene sequences.

The plants produced through the use of these methods are known as either "chimeric" or "transgenic" plants. In a "chimeric" plant, only some of the plant's cells contain and express the introduced gene sequence, whereas other cells remain unaltered. In contrast, all of the cells of a "transgenic" plant contain the introduced gene sequence.

Transgenic plants generally are generated from a transformed single plant cell. Many genera of plants have been regenerated from a single cell.

(Friedt, W. etal. Prog. Botany 49:192-215 (1987); Brunold, C. et al., Molec.

Gen. Genet. 208:469-473 (1987); Durand, J. et al., Plant Sci. 62:263-272 (1989) which references are incorporated herein by reference).

Several methods have been developed to deliver and express a foreign gene into a plant cell. These include engineered Ti plasmids from the soil bacterium A. tumefaciens (Czako, M. et al., Plant Mol. Biol. 6:101-109 WO 93/16096 PCTUS93/01121 -9- (1986); Jones, J.D.G. et al., EMBO J. 4:2411-2418 (1985), engineered plant viruses such as the cauliflower mosaic virus (Shah, D.M. et al., Science 233:478-481 (1986)); Shewmaker, C.K. et al., Virol. 140:281-288 (1985)), microinjection of gene sequences into a plant cell (Crossway, A. et al., Molec.

Gen. Genet. 202:179-185 (1986); Potrykus, I. et al., Molec. Gen. Genet.

199:169-177 (1985)), electroporation (Fromm, M.E. et al., Nature 319:791- 793 (1986); Morikawa, H. et al., Gene 41:121-124 (1986)), and DNA coated particle acceleration (Bolik, M. et al. Protoplasma 162:61-68 (1991)).

The application of the technologies for the creation of transgenic and chimeric plants has the potential to produce plants which cannot be generated using classical genetics. For example, chimeric and transgenic plants have substantial use as probes of natural gene expression. When applied to food crops, the technologies have the potential of yielding improved food, fiber, etc.

Chimeric and transgenic plants having a specific temporal and spatial pattern of expression of the introduced gene sequence can be generated. The expression of an introduced gene sequence can be controlled through the selection of regulatory sequences to direct transcription and or translation in a temporal or spatial fashion.

Summary of the Invention The invention is directed to isolated genomic DNA and cDNA corresponding to the GA1 locus of A. thaliana, vectors containing such DNA, hosts transformed with such vectors, the regulatory regions that control the expression of the GAl protein, and the use of such regulatory sequences to direct the expression of a heterologous gene.

WO 93/16096 PCUS93/01121 The invention further concerns the GAl protein, substantially free of other A. thaliana proteins, antibodies capable of binding the GA1 protein, and the use of such GA1 protein and antibodies thereto.

The invention further concerns chimeric and transgenic plants transformed with the GAl encoding DNA sequence, or transformed with a heterologous gene controlled by the regulatory sequences of the GAl gene.

The invention further concerns the use of sequences encoding the GAl protein and antibodies capable of binding to the GAl protein to detect the expression of GAl and to isolate the regulatory proteins which bind to GAI gene sequences.

Brief Description of the Figures Figure 1. A diagram of the enrichment and cloning method of the preferred embodiment of the present invention. DNA is depicted as a solid line; biotinylated DNA is depicted as a striped black/white line; Sau3a adaptors are shown as an open line; avidin beads are shown as speckled circles; radiolabelled fragments are shown with asterisks.

Figure 2. Genetic and physical maps of the A. thaliana GAI locus.

A: Genetic map in cM X 10' 2 of nine A. thaliana ga-1 alleles (29.9, NG4, d69, A428, d325, 6.59, Bo27, 31.89) (Koornneef et al., Genet. Res.

Camb. 41:57-68 (1983)). The presumptive deletion in 31.89 is indicated by the horizontal line.

B: Physical map of the GAI region. The heavy horizontal line is a HindII restriction map of the Landsberg erecta DNA encompassing the GA-1 locus.

HindIII restriction sites are depicted by vertical ticks extending below the WO 93/16096 PC7/US93/01121 -11horizontal line. The numbers immediately below the heavy horizontal line represent the size, in kilobase pairs, of the respective HindllI restriction fragments. The location of the deletion in 31.89 is indicated by the hatched box. The horizontal lines above the restriction map indicate the extent of the sequences contained in the X clone XGA1-3, the plasmid pGA1-2 (deposited January 7, 1993 pursuant to the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms For The Purposes of Procedure (Budapest Treaty) with the American Type Culture Collection (ATCC) in Rockville, Maryland, U.S.A. 20852, and identified by ATCC Accession No. 75394), and the cosmid clone pGAl-4 (deposited January 7, 1993 pursuant to the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms For The Purposes of Procedure (Budapest Treaty) with the American Type Culture Collection (ATCC) in Rockville, Maryland, U.S.A. 20852, and identified by ATCC Accession No.

75395). The diagram below the horizontal lines depicts the location of introns (lines) and exons (open boxes) of the GA1 gene within the 1.2 kb HindIII restriction fragment and the locations of the insertion mutation in allele 6.59 and the point mutations in alleles, d352, A428 and Bo27.

Figure 3. Detection of deletions and insertions in 31.89 and 6.59 DNA, respectively. Autoradiograms are shown for Southern blots probed with (A) the 250 bp Sau3A fragment from pGAI-1 (see Example and the 6 kb fragment from pGA1-2 (ATCC No. 75394) that covers the entire deleted region in 31.89 (Figure 1B). Both blots A. and B contain HindII-digested DNA isolated from Landsberg erecta (lane and three ga-1 mutants, 31.89 (lane 29.9 (lane and 6.59 (lane The arrows in panel B indicate altered HindIlI fragments in 31.89 (4.2 kb) and 6.59 (1.3 and 3.3 kb).

WO 93/16096 PCT/US93/121 -12- Figure 4. Photograph and Southern blots of wild-type and transgenic plants containing GAI gene.

Photograph of six-week-old A. thaliana Landsberg erecta plants. Left to right: a ga-1 mutant (31.89), a transgenic ga-1 mutant (31.89) plant containing the 20 kb insert from pGA1-4 (ATCC No. 75395), a wild-type Landsberg erecta plant. Autoradiograms are shown for Southern blots probed with the 6 kb fragment from pGA1-2 (ATCC No. 75394), and pOCA18 DNA which is the vector for pGAl-4 (ATCC No. 75395) (see Figure Blots B and C contain HindIII-digested DNA from Landsberg erecta (lane 1 in B), Columbia (lane 2 in B, lane 1 in 31.89 (lane 3 in B, lane 2 in and two T3 generation transgenic ga-1 (31.89) plants transformed with pGA1-4 (ATCC No. 75395) (lane 4,5 in B; lane 3,4 in C).

Figure 5. Detection of a 2.8 kb mRNA using GAJ cDNA probes.

Autoradiogram of an RNA blot probed with a 32 P-labelled 0.9 kb GAl cDNA or cab cDNA (chlorophyll a/b-binding protein gene). RNA was from wild type four-week-old plants (lane five-week-old wild type plants, (lane 2), immature wild-type siliques (lane and four week-old ga-1 mutant 31.89 plants (lane 4).

Figure 6. Partial cDNA sequence of the GA. gene (Sequence ID No. The GA1 DNA strand complementary to GA1 mRNA is shown in a 5'-3' orientation. The GA1 variant d352 has the identical sequence to that shown except for the substitution of an A for the G at position 425. The GA1 variant A428 has the identical sequence to that shown except for the substitution of a T for the C at position 420. The GA1 variant Bo27 has the identical sequence to that shown except for the substitution of a T for the C at position 246.

WO 93/16096 POWS93S8/01121 -13- Figure 7. Partial cDNA sequence of the GAl gene (Sequence ID No. 2).

The GA1 DNA strand shown is analogous to GA1 mRNA and complementary to the strand Fs'own in Figure 6. The GA1 variant d352 has the identical sequence to that shown ept for the substitution of a T for the C at position 479. The GA1 vanant 1-428 has the identical sequence to that shown except for the substitution of an A for the G at position 484. The GA1 variant Bo27 has the identical sequence to that shown except for the substitution of an A for the G at position 658.

Description of the Preferred Embodiments Using genomic subtraction, a gene involved in the synthesis of GA has been isolated. Genomic subtraction is a method for enriching, and clonally isolating a gene sequence present in one nucleic acid population but absent in another. Following the procedures outlined herein that demonstrate the cloning of the GA1 gene, it is now also possible to isolate other genes involved in GA synthesis.

A. The GA-1 gene from A. thaliana Using the technique of genomic subtraction, a gene involved in the synthesis of GA, encoded by the GAl locus of A. thaliana, has been cloned (hereinafter the GA1 gene, Example 1).

In one embodiment of the present invention, vectors containing genomic or cDNA encoding the GAl protein (Sequence ID No. or a fragment thereof, are provided. Specifically, such vectors are capable of generating large quantities of the GA1 sequence, substantially free of other A.

thaliana DNA.

WO 93/16096 PP~rUS93/01121 -14- Vectors for propagating a given sequence in a variety of host systems are well known and can readily be altered by one of skill in the art such that the vector will contain the GAl sequence and will be propagated in a desired host. Such vectors include plasmids and viruses and such hosts include eukaryotic organisms and cells, for example yeast, insect, plant, mouse or human cells, and prokaryotic organisms, for example E. coli and B. sutllus.

As used herein, a sequence is said to be "substantially free of other A.

thaliana DNA" when the only A. thaliana DNA present in the sample or vector is of a specific sequence.

As used herein, a "DNA construct" refers to a recombinant, man-made

DNA.

As used herein, "a fragment thereof" relates to any polynucleotide subset of the entire GAI sequence. The most preferred fragments are those containing the active site of the enzyme encoded by GAl, or the regulatory regions of the GA1 protein and gene respectively.

In a further embodiment of the present invention, expression vectors are described which are capable of expressing and producing large quantities of the GAl protein, substantially free of other A. thaliana proteins.

As used herein, a protein is said to be "substantially free of other A.

thaliana proteins" when the only A. thaliana protein present in the sample is the expressed protein. Though proteins may be present in the sample which are homologous to other A. thaiana proteins, the sample is still said to be substantially free as long as the homologous proteins contained in the sample are not expressed from genes obtained from A. thaliana.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the WO 93/16096 PCT/ US93/01121 DNA sequence sought to be expressed are connected in such a way as to permit gene sequence expression. The precise nature of the regulatory regions needed for gene sequence expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal the initiation of gene synthesis. Such regions will normally include those coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

If desired, the non-coding region 3' to the gene sequence coding for the GA1 gene may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3'-region naturally contiguous to the DNA sequence coding for the GA1 gene, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.

Two DNA sequences (such as a promoter region sequence and the GAl gene encoding sequence) are said to be operably linked if the nature of the linkage between the two DNA sequences does not result in the introduction of a frame-shft mutation, interfere with the ability of the promoter region sequence to direct the transcription of the GAl gene sequence, or interfere with the ability of the GAl gene sequence to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence.

Thus, to express the GAl gene transcriptional and translational signals recognized by an appropriate host are necessary.

WO 93/16096 PCr~/US93/01121 -16- The present invention encompasses the expression of the GA1 gene protein (or a functional derivative thereof) in either prokaryotic or eukaryotic cells. Preferred prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, etc. The most preferred prokaryotic host is E. coli. Bacterial hosts of particular interest include E. coli K12 strain 294 (ATCC 31446), E. coli X1776 (ATCC 31537), E. coli W3110 lambda', prototrophic (ATCC 27325)), and other enterobacterium such as Salmonella typhimurium or Serratia marcescens, and various Pseudomonas species. Under such conditions, the GA1 gene will not be glycosylated. The procaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

To express the GA1 gene (or a functional derivative tiereof) in a prokaryotic cell (such as, for example, E, coli, B. subtilis, Pseudomonas, Streptomyces, etc.), it is necessary to operably link the GAl gene encoding sequence to a functional prokaryotic promoter. Such promoters may be either constitutive or, more preferably, regulatable inducible or derpressible).

Examples of constitutive promoters include the int promoter of bacteriophage X, the bla promoter of the #-lactamase gene sequence of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, etc. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage X (PL and PR), the trp, recA, lacZ, lad, and gal promoters of E. coli, the a-amylase (Ulmanen, et al., J.

Bacteriol. 162:176-182 (1985)) and the sigma-28-specific promoters of B.

subtilis (Gilman, et al., Gene 32:11-20 (1984)), the promoters of the bacteriophages of Bacillus (Gryczan, In: The Molecular Biology of the Bacilli, Academic Press, Inc., NY (1982)), and Streptomyces promoters (Ward, et al., Mol. Gen. Genet. 203:468-478 (1986)).

WO 93/16096 PCrUS93/01121 -17- Prokaryotic promoters are reviewed by Glick, Ind. Microbiol.

1:277-282 (1987)); Cenatiempo, Y. (Biochimie 68:505-516 (1986)); and Gottesman, S. (Ann. Rev. Genet. 18:415-442 (1984)).

Proper expression in a prokaryotic cell also requires the presence of a ribosome binding site upstream of the gene sequence-encoding sequence. Such ribosome binding sites are disclosed, for example, by Gold, et al. (Ann.

Rev. Microbiol. 35:365-404 (1981)).

Preferred eukaryotic hosts include yeast, fungi, insect cells, mammalian cells either in vivo, or in tissue culture. Mammalian cells which may be useful as hosts include cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin, such as the hybridoma SP2/O-AG14 or the myeloma P3x63Sg8, and their derivatives. Preferred mammalian host cells include SP2/0 and J558L, as well as neuroblastoma cell lines such as IMR 332 that may provide better capacities for correct post-translational processing.

For a mammalian host, several possible vector systems are available for the expression of the GAI gene. A wide variety of transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host. The transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, Simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression. Alternatively, promoters from mammalian expression products, such as actin, collagen, myosin, etc., may be employed. Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be modulated. Of interest are regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical (such as metabolite) regulation.

WO 93/16096 PCT/US93/01121 -18- Yeast provides substantial advantages in that it can also carry out posttranslational peptide modifications. A number of recombinant DNA strategies exist which utilize strong promoter sequences and high copy number of plasmids which can be utilized for production of the desired proteins in yeast.

Yeast recognizes leader sequences on cloned mammalian gene sequence products and secretes peptides bearing leader sequences pre-peptides).

Any of a series of yeast gene sequence expression systems incorporating promoter and termination elements from the actively expressed gene sequences coding for glycolytic enzymes produced in large quantities when yeast are grown in mediums rich in glucose can be utilized. Known glycolytic gene sequences can also provide very efficient transcriptional control signals. For example, the promoter and terminator signals of the phosphoglycerate kinase gene sequence can be utilized.

Another preferred host is insect cells, for example the Drosophila larvae. Using insect cells as hosts, the Drosophila alcohol dehydrogenase promoter can be used. Rubin, Science 240.1453-1459 (1988).

Alternatively, baculovirus vectors can be engineered to express large amounts of the GA1 gene in insects cells (Jasny, Science 238:1653 (1987); Miller, etal., in Genetic Engineering (1986), Setlow, etal., eds., Plenum, Vol. 8, pp. 277-297).

As discussed above, expression of the GAl gene in eukaryotic hosts requires the use of eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis. Preferred eukaryotic promoters include the promoter of the mouse metallothionein I gene sequence (Hamer, et al., J. Mol. Appl. Gen. 1:273- 288 (1982)); the TK promoter of Herpes virus (McKnight, Cell 31:355-365 (1982)); the SV40 early promoter (Benoist, et al., Nature (London) 290:304-310 (1981)); the yeast gal4 gene sequence promoter (Johnston, S.A., WO 93/16096 PC/US93/01 121 -19et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975 (1982); Silver, et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955 (1984)).

As is widely known, translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes the GA1 gene (or a functional derivative thereof) does not contain any intervening codons which are capable of encoding a methionine AUG). The presence of such codons results either in a formation of a fusion protein (if the AUG codon is in the same reading frame as the GAl gene encoding DNA sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the GAl gene encoding sequence).

The GA1 gene encoding sequence and an operably linked promoter may be introduced into a recipient prokaryotic or eukaryotic cell either as a non-replicating DNA (or RNA) molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the GAl gene may occur through the transient expression of the introduced sequence.

Alternatively, permanent expression may occur through the integration of the introduced sequence into the host chromosome.

In one embodiment, a vector is employed which is capable of integrating the desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of single chain binding WO 93/16096 PCr/US93/01121 protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama, H., Molec. Cell. Biol. 3:280 (1983).

In a preferred embodiment, the introduced sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species. Preferred prokaryotic vectors include plasmids such as those capable of replication in E. coli (such as, for example, pBR322, ColE1, pSC101, pACYC 184, -rVX. Such plasmids are, for example, disclosed by Maniatis, et al. (In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY (1982)).

Bacillus plasmids include pC194, pC221, pT127, etc. Such plasmids are disclosed by Gryczan, T. (In: The Molecular Biology of the Bacilli, Academic Press, NY (1982), pp. 307-329). Suitable Streptomyces plasmids include pU101 (Kendall, et al., J. Bacteriol. 169:4177-4183 (1987)), and streptomyces bacteriophages such as OC31 (Chater, et al., In: Sixth International Symposium on Actinomycetales Biology, Akademiai Kaido, Budapest, Hungary (1986), pp. 45-54). Pseudomonas plasmids are reviewed by John, et (Rev. Infect. Dis. 8:693-704 (1986)), and Izaki, K. (Jpn.

J. Bacteriol. 33:729-742 (1978)).

Preferred eukaryotic plasmids include BPV, vaccinia, SV40, 2-micron circle, etc., or their derivatives. Such plasmids are well known in the art (Botstein, etal., Miami Wntr. Symp. 19:265-274 (1982); Broach, In: WO) 93/16096 PCT/US93/01121 -21- The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p.

445-470 (1981); Broach, Cell 28:203-204 (1982); Bollon, et al., J. Clin. Hematol. Oncol. 10:39-48 (1980); Maniatis, In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene sequence Expression, Academic Press, NY, pp. 363-608 (1980)).

Once the vector or DNA sequence containing the construct(s) has been prepared for expression, the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means: transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of the GAl gene, or fragments thereof.

This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like).

Following expression in an appropriate host, the GA1 protein can be readily isolated using standard techniques such as immunochromatography or HPLC to produce GAl protein free of other A. thaliana proteins.

By employing chromosomal walking techniques, one skilled in the art can readily isolate other full length genomic copies of GAl as well as clones containing the regulatory sequences 5' of the GA1 coding region.

As used herein, "full length genomic copies" refers to a DNA segment which contains a protein's entire coding region.

As used harein, "regulatory sequences" refers to DNA sequences which are capable of directing the transcription and/or translation of an operably linked DNA sequence. Such regulatory sequences may include, but are not limited to, a promoter, ribosome binding site, and regulatory protein binding WO 93/16096 P(7rUS93/01121 -22site. One skilled in the art can readily identify certain regulatory sequences by comparing sequences found 5' to a coding region with known regulatory sequence motifs, such as those recognized by the computer programs "motif" and "consensus".

In detail, the GA1 DNA sequences disclosed herein were used to screen an A. thaliana genomic DNA library via chromosome walking. Genomic DNA libraries for A. thaliana are commercially available (Clontech Laboratories Inc, and American Type Culture Collection) or can be generated using a variety of techniques known in the art. (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989)). 'By isolating clones which overlap and occur 5' or 3' to the sequences disclosed herein, sequences hybridizing to Sequence ID No. 1 were identified and isolated. Such sequences are contained in the vectors PGA1-4 (ATCC No.

75395) and XGA1-3.

Regulatory sequences are those which occur 5' to a coding region.

The preferred regulatory sequences of the present invention are those which appear from about -2 kb 0 bp 5' of the GAl starting codon (AGT/Met). The more preferred sequences appear from about -500 bp -0 bp, the most preferred being sequences from about -250 bp 0 bp.

Using techniques known in the art and the clones described herein, it is now possible to generate functional derivatives of the GA1 gene as well as the regulatory sequence of this gene. Such derivatives allow one skilled in the art to associate a given biological activity with a specific sequence and/or structure and then design and generate derivatives with an altered biological or physical property.

The preparation of a functional derivative of the GAl sequence can be achieved by site-directed mutagenesis. (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989)). Site-directed mutagenesis allows the production of a functional derivative through the use WO 93/16096 PCF/US9/01121 -23of a specific oligonucleotide which contains the desired mutated DNA sequence.

While the site for introducing a sequence variation is predetermined, the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at a target region and the newly generated sequences can be screened for the optimal combination of desired activity.

The functional derivatives created this way may exhibit the same qualitative biological activity as the naturally occurring sequence when operably linked to a heterologous gene. The derivative may however, differ substantially in such characteristics as to the level of induction in response to phytohormones.

It is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so. One skilled in the art will recognize that the functionality of the derivative can be evaluated by routine screening assays.

For example, a functional derivative made by site-directed mutagenesis can be operably linked to a reporter gene, such as P-glucuronidase (GUS), and the chimeric gene can then be quantitatively-screened for phytohormone responsiveness in chimeric or transgenic plants, or in a transient expression system.

Using a reporter gene and the GAI regulatory elements, mutations which alter tissue specificity and strength of the GA1 promoter can be generated. By analyzing the sequence of the GAl regulatory elements, one skilled in the art will recognize the various protein binding motifs present in the GA1 promoter, and direct mutagenesis activity to these regions.

In another embodiment of the present invention, antibodies which bind the GAl protein are provided.

In detail, an antibody which binds to the GAl protein can be generated in a variety of ways using techniques known in the art. Specifically, in one WO 93/16096 PCT/US93/01121 -24such method, GA1 protein purified from either an expression host or from plant tissue is used to immunize a suitable mammalian host. One skilled in the art will readily adapt known procedures in order to generate both polyclonal and monoclonal anti-GAl antibodies. (Harlow, Antibodies, Cold Spring Harbor Press (1989)).

Alternatively, anti-GAl antibodies can be generated using synthetic peptides. Using the deduced amino acid sequence encoded by the GA1 gene described herein, a synthetic peptide can be made, such that when administered to an appropriate host, antibodies will be generated which bind to the GA1 protein.

In a further embodiment of the present invention, a procedure is described for detecting the expression of the GA1 gene or the presence of the GAl protein in a cell or tissue.

Specifically, using the antibodies and DNA sequences of the present invention, one skilled in the art can readily adapt known assay formats such as in situ hybridization, ELISA, and protein or nucleic acid blotting techniques, in order to detect the presence of RNA encoding GA1, or the GAI protein itself. Utilizing such a detection system, it is now possible to identify the specific tissues and cells which transcribe or translate the GAl gene.

B_ Transgenic or chimeric plants containing genes whose expression mimics the GAl gene.

In another embodiment of the invention, a method for creating a chimeric or transgenic plant is described in which the plant contains one or more exogenously supplied genes which are expressed in the same temporal and spatial manner as GAI.

In detail, a chimeric or transgenic plant is generated such that it contains an exogenously supriled expression module. The expression module WO 93/16096 PCT/US93/01121 comprises the regulatory elements of the GAl gene, operably linked to a heterologous gene.

As described earlier, the regulatory region of the GA1 gene is contained in the region from about -2 kb to 0 bp, 5' to the GAl start codon (Met). One skilled in the art can readily generate expression modules containing this region, or a fragment thereof.

Methods for linking a heterologous gene to a regulatory region and the subsequent expression of the heterologous gene in plants are well known in the art. (Weissbach et al., Methods for Plant Molecular Biology, Academic Press, San Diego, CA (1988)). One skilled in the art will readily adapt procedures for plant cell transformation, such as electroporation, Ti plasmid mediated transformation, particle acceleration, and plant regeneration to utilize the GA1 regulatory elements. In an expression module all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed with the expression module of the present invention. The efficacy of expression will vary between plant species depending on the plant utilized. However, one skilled in the art can readily determine the plant varieties in which the GA1 regulatory elements will function, In another embodiment of the present invention, a method of modulating the translation of RNA encoding GAl in a chimeric or transgenic plant is described.

As used herein, modulation entails the enhancement or reduction of the naturally occurring levels of translation.

Specifically, the translation of GAl encoding RNA can be reduced using the technique of antisense cloning. Antisense cloning has been demonstrated to be effective in plant systems and can be readily adapted by one of ordinary skill to utilize the GA1 gene. (Oeller et al., Science 254:437- 439 (1991)).

WO 93/16096 PCT/US93/01121 -26- In general, antisense cloning entails the generation of an expression module which encodes an RNA complementary (antisense) to the RNA encoding GAI (sense). By expressing the antisense RNA in a cell which expresses the sense strand, hybridization between the two RNA species will occur resulting in the blocking of translation.

In another embodiment of the present invention, a method of modulating the activity of the GAI protein is described.

Specifically, the activity of GAI can be suppressed in a transgenic or chimeric plant by transforming a plant with an expression module which encodes an anti-GAl antibody. The expressed antibody will bind the free GAl and thus impair the proteins ability to function.

One skilled in the art will recognize that DNA encoding an anti-GAI antibody can readily be obtained using techniques known in the art. In general, such DNA is obtained as cDNA, generated from mRNA which has been isolated from a hybridoma producing anti-GAl antibodies. Methods of obtaining such a hybridoma are described earlier.

C. A system for the study of gene expression in plants In another embodiment of the present invention, a method is described to identify the molecular interaction and the proteins responsible for the induction of the GA1 gene.

In detail, using the regulatory sequences of the GA1 gene, it is now possible to isolate the proteins which bind to these sequences.

Procedures for the isolation of regulatory factors capable of binding to a specific DNA sequence are well known in the art. One such method is affinity chromatography. DNA containing the regulatory sequence is immobilized on an appropriate matrix, such as Sepharose, and used as an affinity matrix in chromatography (Arcangioli et al., Eur. J. Biochem.

179:359-364 (1989)).

WO 93/16096 PCTr/US93/01121 -27- Proteins which bind the GAl regulatory element can be extracted from plant tissues expressing the GAl gene. A protein extract obtained in such a fashion, is applied to a column which contains immobilized GAl regulatory region. Proteins which do not bind to the DNA sequence are washed off the column and proteins which bind to the DNA sequence are removed from the column using a salt gradient. The DNA binding protein obtained this way can be further purified using procedures such as ion exchange chromatography, high performance liquid chromatography, and size exclusion chromatography.

During the purification of the DNA binding protein, the protein can be readily assayed using a gel retardation assay (Garner, M.M. et al., Nucl. Acid Res. 9:3047 (1981) and Fried, M. et al., Nucl. Acid Res. 9:6506 (1981)).

Once the DNA binding protein has been purified, a partial amino acid sequence can be obtained from the N-terminal of the protein. Alternatively, the protein can be tryptically mapped and the amino acid sequence of one of the fragments can be determined.

Next, the deduced amino acid sequence is used to generate an oligonucleotide probe. The probe's sequence can be based on codons which are known to be more frequently used by the organism (codon preference), or, alternatively, the probe can consist of a mixture of all the possible codon combination which could encode the polypeptide (degenerate).

Such a probe can be used to screen either a cDNA or genomic library for sequences which encode the DNA binding protein. Once the gene encoding the DNA binding protein has been obtained, the sequence of the DNA encoding the binding protein can be determined, the gene can be used to obtain large amounts of the protein using an expression system, or in mutational analysis can be performed to further define the functional regions within the protein which interacts with the DNA.

WO 93/16096 PCr/US93/01121 -28- Alternatively, proteins which bind to the GA1 regulatory elements can be isolated by identifying a clone expressing such a protein using the technique of Southwestern blotting (Sharp, Z.D. etal., Biochim BiophysActa, 1048:306- 309 (1990), Gunther, C. V. etal., Genes Dev. 4:667-679 (1990), and Walker, M.D. et al., Nucleic Acids Res. 18:1159-1166 (1990)). In a Southwestern blot, a labeled DNA sequence is used to screen a cDNA expression library whose expressed proteins have been immobilized on a filter via colony or plaque transfer. The labeled DNA sequences will bind to colonies or plaques which express a protein capable of binding to the particular DNA sequence.

Clones expressing a protein which binds to the labeled DNA sequence can be purified and the cDNA insert which encodes the DNA binding protein can be isolated and sequenced. The isolated DNA can be used to express large amounts of the protein for further purification and study, to isolate the genomic sequences corresponding to the cDNA, or to generate functional derivative of the binding protein.

D. DNA Homologous to GAl Isolated From Other Plant Species Using the DNA sequences isolated from A. thaliana thus far described, it is now possible to isolated homologous sequence from other plant varieties.

Specifically, using the GA1 DNA sequence of Sequence ID No. 1, or a fragment thereof, one skilled in the art can use routine procedures and screen either genomic or cDNA libraries from other plant varieties in order to obtain homologous DNA sequences. By obtaining homologous sequences, it is now possible to study the evolution of the GA1 gene within the plant kingdom.

Additionally, by examining the differences in enzymatic activity of GA1 isolated from a variety of sources and correlation the differences with WO 93/16096 PCT/US93/01121 sequence divergence, it is now possible to associate specific functional variations with egions within the protein.

The invention thus far described has been directed to the GAl gene.

One skilled in the art will recognize that the procedures described herein can be used to obtain DNA encoding other enzymes responsible for GA synthesis.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

EXAMPLES

EXAMPLE 1 Genomic subtraction between A. thaliana Landsberg erecta DNA and gal 31.89 DNA was performed as described previously (Straus and Ausubel, Proc. Natl. Acad. Sci. USA 87:1889-1893 (1990)) with the following modifications.

A. thaliana Landsberg erecta DNA and gal mutant (31.89) DNA were isolated and purified by CsCI gradient centrifugation as described (Ausubel et al., in Current Protocols in Molecular Biology, Vol. 1 (Greene Publishing Asscciates/Wiley-Interscience, New York, 1990)). In the first cycle of subtraction, 0.25 tAg of Landsberg erecta DNA digested with Sau3A was hybridized with 12.5 of the gal mutant 31.89 DNA that had been sheared and photobiotinylated. 10 cg of biotinylated 31.89 DNA was added in each additional cycle. Hybridizations were carried out for at least 20 hours at a concentration of 3 pg DNA/il at 65°C. After five cycles of subtraction, the amplified products were ligated to Sau3A adaptors, amplified by PCR and ligated into the Smal site of pUC 13.

WO 93/16096 PCY/US93/01121 After five cycles of subtractive hybridization, the remaining DNA fragments were enriched for sequences present in wild-type DNA but missing from 31.89 DNA. These DNA fragments were amplified by the polymerase chain reaction (PCR) and cloned. One of six clones examined (pGAl-1) contained a 250 bp Sau3A fragment that was deleted from 31.89 DNA.

1 ,Ig HindlII-digested DNA from Landsberg erecta and gal alleles 31.89, 29.9, and 6.59 was fractionated on a 1 agarose gel, transferred to GeneScreen membrane (New England Nuclear), and probed with the 250 bp and 6 kb inserts in pGAl-1 and pGA1-2 (ATCC No. 75394) that had been gel-purified and labelled with 32 P, Figure 3. Hybridization conditions were the same as described in Church and Gilbert, Proc. Natl. Acad. Sci. USA 81:1991-1995 (1984).

The insert in pGA1-1 hybridized to a 1.4 kb HindI fragment in DNA samples isolated from wild-type Landsberg erecta and from the gal mutants 29.9 and 6.59 but did not hybridize to 31.89 DNA (Figure 3A), To determine the extent of the deletion in 31.89 DNA identified by pGAI-1, pGAI-1 DNA was used as a hybridization probe to isolate larger genomic fragments corresponding to the deletion in 31.89. These cloned fragments are shown in Figure 2B.

XGA1-3 was isolated from a Landsberg erecta genomic library constructed in XFIX (Voytas et al., Genetics 126:713-721 (1990)) using 3

"P-

labelled pGA1-1 as probe. pGA1-2 (ATCC No. 75394) was obtained by ligating a 6 kb Sall-EcoRI fragment from XGA1-3 into the XhoI and EcoRI sites of pBluescriptll SK (Stratagene). pGAI-4 (ATCC No. 75395) was isolated from a genomic library of A. thaliana ecotype Columbia DNA constructed in the binary vector pOCA18 (Olszewski et al., Nucl. Acid Res.

16:10765-10782 (1988)) which contains the T-DNA borders required for efficient transfer of cloned DNA into plant genomes (Olszewski et al., Nucl.

Acid Res. 16:10765-10782 (1988)).

WO 93/16096 PCr/UeS93/01121 -31- Plasmid pGA1-2 (ATCC No. 75394) containing a 6 kb fragment spanning the insert in pGAl-1 (Figure 2B), was used to probe a Southern blot containing HindIII-digested DNA from wild-type A. thaliana and from several gal mutants. As shown in Figures 3B and 4B, pGA1-2 (ATCC No. 75394) hybridized to four HindI fragments (1.0 kb, 1.2 kb, 1.4 kb and 5.6 kb) in wild-type DNA that were absent in DNA from 31.89 mutants. The deletion mutation produces an extra HindlII fragment (4.2 kb) in 31.89 DNA. These results and additional restriction mapping (not shown) showed thst the deletion in 31.89 DNA is 5 kb, corresponding to 0.0)J5% of the A. thaliana genome (5 kb/10 5 kb) (See Figure 2B).

Three lines of evidence indicate that the characterized 5.0 kb deletion in mutant 31.89 corresponds to the GAl locus. First, RFLP mapping analysis carried out by the procedure detailed in Nam, H.G. et al. Plant Cell 1:699- 705 (1989), using XGA1-3 (Figure 2B) as a hybridization probe showed that XGA1-3 maps to the telomere proximal region at the top of chromosome r, consistent with the location to which the GAl locus had been mapped previously by Koornneef et al. Hered. 74:265-272 (1983)).

Second, a cosmid clone pGA1-4 (ATCC No. 75395) (Figure 2B), which contains a 20 kb insert of wild-type (Columbia) DNA spanning the deletion in 31.89, complemented the ga-1 mutation in 31.89 as determined by the phenotype of Agrobacterium tumefaciens-mediated transformants (Figure 4A).

Agrobacterium tumefaciens strain LBA4404 containing pGA1-4 was used to infect root explants of gal mutant 31.89 and kanamycin-resistant (Kmn) transgenic plants were selected as described (Valvekens et al., Proc. Natl.

Acad. Sci. USA 85:5536-5540 (1988)). 130 Km' plants were regenerated which set seeds in the absence of exogenous GA (T1 generation). 50 to 300 seeds from each of 4 different T1 plants showed 100% linkage of the gal and WO 93/16096 PCT/US93/01121 -32- Km' phenotypes which segregated approximately 3:1 to the gal/Km" phenotype (T2 generation).

Seeds of transgenic gal and wild-type plants were germinated on agarose plates containing 1X Murashige Skoog salts and 2% sucrose with or without kanamycin (MS plates). Seeds of the gal mutant 31.89 were soaked in 100 /zM GA 3 for 4 days before being germinated on MS plates. Seven-dayold seedlings were transferred to soil.

To show the dwarf phenotype, no additional GA 3 was given to the mutant 31.89 after germination. Southern blot analyses were carried out as described for Figure 3. The insert in pGA1-4 (ATCC No. 75395) was isolated from the Columbia ecotype. As seen in lanes 1 and 2 in panel B, pGA1-2 (ATCC No. 75394) detected an RFLP between the Lardsberg (5.6 kb) and Columbia (5.0 kb) DNAs. The DNA in lanes 1, 2, and 3 in panel B was purified by CsCI density gradient centrifugation whereas the DNA in lanes 4 and 5 in panel B was purified by a miniprep procedure. This explains the minor differences in mobilities of the hybridizing bands in lanes 1, 2, and 3 compared to lanes 4 and Several independent T2 generation transgenic plants, containing the insert of pGA1-4 (ATCC No. 75395) integrated in the 31.89 genome, did not require exogenous GA for normal growth. Germination, stem elongation, and seed set were the same in the transgenic plants as in the wild-type plants without exogenous GA treatment. Southern blot analysis, using the 6 kb fragment from pGA1-2 (ATCC No. 75394) as a probe, indicated that both the endogenous gal 31.89 locus (4.2 kb) and wild-type GA1 DNA 1.4, 1.2 and 1.0 kb HindlII fragments) were present in two independent T3 generation tiansgenic plants (Figure 4B).

Further Southern blot analysis, using the vector pOCA18 which contains the T-DNA border sequences as a probe, showed that only two border fragments were present in the genomes of both transgenic plants WO 93/16096 PCT/rS93/01121 -33- (Figure 4C). These results indicated that the wild-type GAl DNA was integrated at a single locus in the genomes of both transgenic plants.

Third, to obtain unequivocal evidence that the 5.0 kb deletion in 31.89 corresponds to the GAl locus, we showed that four additional gal alleles contain alterations from the wild-type sequence within the region deleted in 31.89 in the order predicted by the genetic map. To aid in this analysis, a partial GA1 cDNA clone (0.9 kb) (Sequence ID No. containing poly A and corresponding to the 1.2 kb HindI fragment (Figure 2B), was isolated from a cDNA library constructed from RNA isolated fron siliques (seed pods) of A. thaliana ecotype Columbia. Four exons and three introns in the 1.2 kb HindII fragment were deduced by comparison of the cDNA and genomic DNA sequences (Figure 2B, sequence data not shown). The identification of this cDNA clone showed that the 1.2 kb HindIII fragment is located at the 3' end of the GAl gene and suggested that the mutations in the gal alleles 31.89, Bo27, 6.59, d352, and A428 should also be located at the 3' end of the GAl gene.

In addition to the 31.89 allele, two other gal alleles, 6.59 and 29.9, were induced by fast neutron mutagenesis (Koornneef et al., Genet. Res.

Camb. 41:57-68 (1983)). As shown in Figure 3B, the 1.2 kb HindIII fragment in 6.59 DNA was replaced by two new fragments of 1.3 kb and 3.3 kb without alteration of the adjacent 1.4 kb and 5.6 kb fragments. Further Southern blot analysis and direct DNA sequencing of PCR products from 6.59 DNA templates indicated that the 6.59 allele contains a 3.4 kb or larger insertion in the 1.2 kb HindIII fragment in the last intron defined by the cDNA clone (Figure 2B). Southern blot analyses, using pGA1-2 (ATCC No. 75394) (Figure 2B) and pGA1-4 (ATCC No. 75395) as probes, showed that there are no visible deletions or insertions in 29.9 DNA. Three additional gal alleles, A428, d352 and Bo27, are located at or near the 6.59 allele on the genetic map (Figure 2A). Direct sequencing of PCR products amplified from Bo27, WO 93/16096 PCT/US93/01121 -34- A428, and d352 mutant DNA templates revealed single nucleotide changes within the last two exons in the 1.2 kb HindlII fragment in all three mutants (Figure 2B). Mutant Bo27, which defines one side of the genetic map, contained a single nucleotide change in the most distal GAl exon. The single nucleotide changes in mutants Bo27, A428, and d352 result in missense mutations, consistent with the leaky phenotypes of mutants A428 and d352 (Koornneef et al., Genet. Res. Camb. 41:57-68 (1983)). It is unlikely that the base changes observed in mutants Bo27, A428, and d352 are PCR artifacts or are due to the highly polymorphic nature of the GA1 locus because the 1.2 kb Hindll fragment amplified and sequenced from mutants NG4 and NG5 both had the wild-type sequence. Moreover, the PCR products were sequenced directly and the sequence analysis was carried out twice using the products of two independent amplifications for each allele examined.

We used the recombination frequency between different gal alleles reported by Koornneef et al. (Genet. Res. Camb. 41:57-68 (1983)) to calculate that the recombination frequency per base pair is approximately 10' 5 cM within the GAl locus. This calculation is based on the reported recombination frequency of 0.5 X 102 cM between gal alleles A428 or d352 and Bo27 (Figure 2A) and our observation that the mutations in d352 and Ro27 and in A428 and Bo27 are separated by 432 and 427 bp, respectively. This calculation suggests that the extent of the entire GAl locus defined by mutants 29.9 and Bo27 is approximately 7 kb. The predicted size of this locus can accommodate the 2.8 kb mRNA detected in wild-type plants using the GAl cDNA as a hybridization probe (Figure Poly(A) +RNA of four-week-old and five-week-old plants was prepared from the entire plant except the roots and silique RNA was prepared from immature siliques plus some flower buds and stems as previously described (Ausubel et al., in Current Protocols in Molecular Biology, Vol. 1 (Greene Publishing Associates/Wiley-Interscience, New York, 1990); Maniatis et al., WO 93/16096 POW~hS93/01121 in Molecular Cloning: A Laboratory Manual, 197-201 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982)). Approximately 2 micrograms of RNA of each sample was size-fractionated on a 1 agarose gel (Maniatis et al., in Molecular Cloning: A Laboratory Manual, 197-201 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982)), transferred to GeneScreen membrane, and hybridized with a "P-labelled 0.9 kb EcoRI DNA fragment from the GAl cDNA (Figure The RNA blot was also hybridized with a 3 P-labelled 1.65 kb EcoRI fragment containing the A. thaliana cab gene (AB 165) (Leutwiler et al., Nucl. Acid Res. 14:4051-4064 (1986)).

Decreased hybridization of the cab probe in lane 3 reflects the fact that the cab gene is not highly expressed in siliques.

As expected, the 2.8 kB RNA could not be detected in the deletion mutant (figure The linkage map of A. thaliana is approximately 600 cM and the genome size is approximately 1.08 x 10' bp (Goodman et at., unpublished results). This is equivalent to approximately 6 x 10' cM per base pair, in good agreement with the observed recombination frequency in the GAl locus.

Cloning the A. thaliana GAl gene presented a variety of experimental opportunities to investigate the regulation and the site of GA biosynthesis.

Because ent-kaurene is the first committed intermediate in GA biosynthesis, it is likely that the GA1 gene, required for the formation of ent-kaurene, is a point of regulation for GA biosynthesis (Graebe, Ann. Rev. Plant Physiol. 38:419-465 (1987); Moore, in Biochemistry and Physiology of Plant Hormones, 113-135 (Springer-Verlag, New York, 1989)). Indeed, the biosynthesis of ent-kaurene has been shown to occur preferentially in rapidly developing tissues, such as immature seeds, shoot tips, petioles, and stipules near the young elongating internodes (Moore, in Biochemistry and Physiology of Plant Hormones, 113-135 (Springer-Verlag, New York, 1989); Chung and Coolbaugh, Plant Physiol. 80:544-548 (1986)).

WO 93/16096 PCT/US93/01121 -36- Genomic subtraction is not labor intensive and the results reported here indicate that genomic subtraction could be routinely used to clone other nonessential A. thaliana genes if a method were available for generating deletions at high frequency. In addition to the gal deletion in mutant 31.89 induced by fast neutron mutag-,esis (Koornneef et al., Genet. Res. Camb. 41:57-68 (1983); Dellaert, "X-ray- and Fast Neutron-Induced Mutations in Arabidopsis thaliana, and the Effect of Dithiothreitol upon the Mutant Spectrum," Ph.D. thesis, Wageningen (1980); Koorneef et al., Mutation Research 93:109-123 (1982)), X-ray- and *y-ray- irradiation have also been shown to induce short viable deletions in A. thaliana at the chl-3 (Wilkinson and Crawford, Plant Cell 3:461-471 (1991)), tt-3 Shirley and H. M.

Goodman, unpublished result) and gl-1 loci Marks, personal communication).

EXAMPLE 2 Expression of Antisense GA1 RNA.

An expression vector is constructed as previously described such that it expresses an RNA complementary to the sense strand GA1 RNA. The antisense GA1 RNA is expressed in a constitutive fashion using promoters which are constitutively expressed in a given host plant, for example, the cauliflower mosaic virus 35S promoter. Alternatively, the antisense RNA is expressed in a tissue specific fashion using tissue specific promoters. As described earlier, such promoters are well known in the art.

In one example, the antisense construct pPO35 (Oeller et al., Science 254:437-439 (1991)) is cut with BamH1 and SAC1 to remove the tACC2 cDNA sequence. After removing the tACC2 cDNA, the vector is treated with WO 93/16096 K =T/US93/01121 -37the. Klenow fragment of E. coli DNA polymerase I to fill in the ends, and the sequence described in SEQ ID. NO. 1 is blunt end ligated into the vector.

The ligated vector is used to transform an appropriate E. coli strain.

Colonies containing the ligated vector are screened using colony hybridization or Southern blotting to obtain vectors which contain the GA1 cDNA in the orientation which will produce antisense RNA when transcribed from the 35S promoter contained in the vector.

The antisense GA1 vector is isolated from a colony identified as having the proper orientation and the DNA is introduced into plant cells by one of the 10 techniques described earlier, for example, electroporation or Agrobacterium/Ti plasmid mediated transformation.

Plants regenerated from the transformed cells express antisense GA1 RNA. The expressed antisense GA1 RNA binds to sense strand GA1 RNA and thus prevent translation.

CONCLUSION

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

pC'/US93/01 121 WO 93/16096 -3 SEQUENCE LISTING GENERAL INFORMATION: Wi APPLICANT: SUN, TAI-PING GOODMAN,* HOWARD M.

AUSUBEL, FREDERICK M.

(ii) TITLE OF INVENTION: Recombinant Gibberillin DNA and Uses Thereof (iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: Sterne, Kessler, Goldstein &Fox STREET: 1225 Connecticut Avenue CITY: Washington STATE: D.C.

COUNTRY% U.S.A.

ZIP: 20036 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COM4PUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/M.S-DOS SOFTWARE: Patentln Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: US (to be assigned) FILING DATE: Herewith

CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMAiTION: NAME: Cimbala, Michele A.

REGISTRATION NUMBER: 33,851 REFERENCE/DOCKET NUMBER: 0609.3750004 (ix) TELECOM4MUNICATION INFORMATION- TELEPHONE: (202) 466-0800 TELEFAX: (202) 833-8716 INFORMATION FOR SEQ ID NO:l: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: both TOPOLOGY: 1/.near (xi) SEQUENCE DESCRIPTION: SEQ ID 140:1: CTGCAGGAAT TCCTTTTTT TTT'1TTTT TGGCTTTGAG TATATATACT TTGAAATATA TTCATATAAA AATAGAATGT CCAACACACA AACCTTGTAA GCTTTAGCTC- AGAATCGTAC GGTACATCAA TG-1 A rCC TACTTCGAAT CCGATTGGCA TATGCTCATC CCGGAAAAAC GTGATTCCTT TGTTGCATTG AACGACGCAT GCAAGGGTAT TGATGAGACG CCAAGAACCA TCGGAAAGTT GGTTCTCCGC AGTTTTATCT CCGGCATCGA TCAATGCAAC TTCCCCGTCC GTTAGGTTTC TCAAGATCGT ATTACTATTA CTTCCAACAC TAATCTGAGG ATGTATTAGA GGCAAATCAT GTTGAACCTrC CTrTTGAMCM TGTATGGAAC CG;CTTCTGGA

TTTCTTGGCG

TCGAGCTATC

ATTTCGTCT

ATGAGGAAAG

ATCATGATAA

GATCCATTTC

CCAAGCTGTA

TTTCACACTC

TGAAGTACAT

TCAAATGTAT

TATATATCTT

TCAAGCAACG

TCTAGCTTCC

AGATTCCATG

GAGAAGAGAT

ACGGCGGAGG

TCGTA.AGCCG

TTCACTGCTT

AGGACCCATC

ATTTTTTGGC

TTAAGACCGG

ATGGGAATGC

CAATATTT'TC

ATCTTAGAGC

ACGCATCTCC

GAAACGCCGG

ATATCGTAAT

CTTTGAATGC

GTTGCCACTC AGCATCTTCT CCTTGAAGCT TTGAGAATTA ATGTATTCTT GAGTTCGAAG TrTTGTCTCTA GCGACATTGA GAGGAGATCC PCT/US93/01 121 WO 93/16096 39 TGAGATGGTA AGGAAAGAAG AAGATATTGT TGTTTTAGTA, GAACTGAGAA AGGTTGTACT TGGAATGGAG TTTAGAACAT GATACTGAAG AGACATGGCT TTA~JAAJAA AAAAAAGGAA

TTC

INFORMATION FOR SEQ ID NO:2: i)SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: both TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GAATYCCTTT TTITTTTTTTY TAAAGCCATG TCTCTTCAGT CCAAGTACAA CCTTTCTCAG TTCTACTAAA ACAACAATAT ATCATGTTCT AAACTCCATI CTTCTIT:. 2 CCTrACCATC TCAGGATCTC CTCTCAATGT AAGCTTCGAA CTCAAGAATA CATGAGTGGC AACAGCTTCA AATGCATTCA AAGAAGCAGT GAAATTACGA TATCGGCTTA ACTCCGGCGT TTCCCTCCGC TGGGGAGATG CGTATCTCTT GTTGCTCTAA GATCATGGAA CGGGAAAATA TTGGGAAGCT GTAGCATTCC CATCGTTGCT TCTCCGGTCT TAAAAGATAT TGGGCCAAAA AATATACATT CGCTAGAGAC AAATCCAGAA GCGGTTCCAT ACATTGTTCA CA7-&AATTCT CAAGAGGTTC AACATGATI'T GCCTCTAATA AGGAGAAGAT GCTCCTCAGA TTAGTGTTGG AAGTAATAGT GAAGAGTGTG AAAACGATCT TGAGAAACCT AACGGACGGG CGATACAGCT TGGGTTGCAT TGATCGATGC CGTGAAATGG ATCGCCGAGA ACCAACTTTC CTCTTATCAT GATCCTCTCA TCAATACCCT TCTCTr1CCT CTCAATGCA ACAAAGGAAT AGAAGACGAA AATGATGACC ATATGCCAAT TGAGATAGCT CGAGGAATAA ACATTGATGT ATACGCCAAG AhAGAGCTAA AGCTTACAAG TGAACATTCT ATTTTTATAT GAATATATT

CGGAGATAAA

CGATGGTTCT

TGCATGCGTC

CACGITTITC

CGGATTCGAA

ACCGMhCGAT

GTTTGTGTGT

CAAAGTATAT

ATAGATGGGT CCTATGTACT TCACTCAAAG CCAAAAAAAA AAAAAAAAAA GGAhTTCCTG

CAG

ni I I A<tknt Vr-r/T lQ011111 1171 ~Vl.J 7..M AUU7U -40- '5 INDICATIONS RELATIlNG TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) A. The indications madc b~aow relate to the micoorganism referred to in the desciption on page 11 ,line B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet [My Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit Accession Number 07 January 1993 75394 C. ADDITIONAL INDICATIONS (leave blank if"oeppicable) This information is continued on an additional sheet Plasmid DNA, pGAl-2 In respect of those designations in which a European Patent is sought a samnple of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 EPC).

D. DESIGNATED STATES FOR WHICH INDICATIONS ARIE MADE (ifth iasaore nforall desigaaed~aes) E. SEPARATE FURNISHING OF INDICATIONS (leave blank ifxwo applicable) The indications listed below will be submitted to the International Bureau later (specfyhiegeneral nature of tieindi cations eg., 'Accession Number of Deposit') For receiving Office use only For International Bureau use only j'This sheet was received with the international application I J F-This sheet was received by the International Bureau on: Auth of ice &OAL.V1 Form YbCT/RO/134 (July 1992) Authorized officer WO 93/16096 PCT/US93/01121 -41- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) A. The indications made below relate to the microorganism referred to in the description on page 11 ,line B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit Accession Number 07 January 1993 75395 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet j Cosmid DNA, pGAl-4 In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (ifthe indications are notfor all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank ifnot applicable) The indications listed below will be submitted to the International Bureau later (specifythe generalnatureoftheindicationse.g., "Accession Number of Deposit") S For receiving Office use only SThis sheet was received with the international application Authorized officer lifnri'CLr/) 134 (JulVl 992 K S For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

Claims (14)

1. A DNA construct comprising the DNA sequence of the GA1 gene of Arabidopsis thaliana.

2. The regulatory DNA sequences of the GA1 gene of Arabidopsis. substantially free of DNA sequence encoding the GA1 protein.

3. A vector containing the sequences of claims 1 or 2.

4. A host transformed with one of the vectors of claim 3.

5. The host of claim 4, wherein said host is selected from the group consisting of bacteria, yeast, plants, insects or mammals.

6. A method of directing the expression of a gene in a plant, such that said gene has the same temporal and spatial expression pattern of GA1 of Arabidopsis, said method comprising the steps of':- 1) operably linking said gene to the regulatory DNA sequences of GA1 to create an expression module, and 2) transforming said plant with said expression module.

7. The method of claim 6 wherein said regulatory DNA sequences comprise the sequences from about -2 kb to 0 bp, 5' of the GA1 coding region. (41 43

8. The method of claim 6 wherein said regulatory DNA sequences comprise the sequences from about -500 bp to 0 bp, 5' of the GA1 coding region.

9. The method of claim 6 wherein said regulatory DNA sequences comprise the sequences from about -250 bp to 0 bp, 5' of the GA1 coding region.

A method of modulating the translation of RNA encoding GA1 of Arabidopsis in a plant comprising the steps of: 1) generating an expression vector encoding antisense GA1 RNA; and 2) transfecting said plant with said expression vector.

11. A method of modulating the activity of the GA1 protein of Arabidopsis in a plant comprising the steps of 1) generating an expression vector encoding an antibody, or fragment thereof, capable of binding to the GA1 protein; and 2} transforming said plant with said expression vector.

12. An antibody or fragment thereof, capable of specifically binding the GA1 protein of Arabidopsis.

13. A protein capable of specifically binding to the regulatory region of the GA1 gene of Arabidopsis. 44

14. A method of identifying cells or tissues expressing GA1 of Arabidopsis comprising the steps of: 1) incubating said cells or said tissues with an agent capable of specifically binding to the GA1 protein or the RNA encoding GA1; and 2) detecting the presence of bound agent. The method of claim 14 wherein said agent capable of specifically binding to the GA1 protein is an antibody, or fragment thereof. i« *16. The method of claim 14 wherein said agent capable of binding to the RNA encoding GA1 is selected from the group consisting of RNA and DNA. 0 Dated this 19 day of December 1996 PETER MAXWELL ASSOCIATES